The Technical Analyst
Morphic Holding Inc [MORF]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Morphic Holding Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.29% $27.51
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 376.52 mill |
| EPS: | -3.59 |
| P/E: | -7.66 |
| Earnings Date: | Apr 23, 2024 |
| SharesOutstanding: | 50.04 mill |
| Avg Daily Volume: | 0.504 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.30x |
| Company: PE -7.66 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.084 (-96.06%) $-26.43 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 25.68 - 29.34 ( +/- 6.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Rogers Bruce | Buy | 7 400 | Common Stock |
| 2024-03-27 | Rogers Bruce | Sell | 7 400 | Stock Option (right to buy Common Stock) |
| 2024-03-18 | Cooper Simon Peter | Buy | 170 000 | Employee Stock Options (right to buy) |
| 2024-03-18 | Cooper Simon Peter | Buy | 14 000 | Restricted Stock Unit |
| 2024-03-18 | Cooper Simon Peter | Buy | 7 000 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 69.60 |
| Last 99 transactions |
| Buy: 2 671 692 | Sell: 511 174 |
Forecast:
16:00 - $27.50
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $27.50
Forecast 2: 16:00 - $27.50
Forecast 3: 16:00 - $27.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $27.51 (-1.29% ) |
| Volume | 0.296 mill |
| Avg. Vol. | 0.504 mill |
| % of Avg. Vol | 58.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MORF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:31 | buy | $38.74 | N/A | Active |
|---|
MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2024-04-16 23:30:00 - Press Release
Ongoing Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Morphic Holding, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 16, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of morphic holding, inc. ("morphic" or "the company") (nasdaq:morf) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-15 03:00:00 - Press Release
Important Investor Alert: The Schall Law Firm Announces It Is Investigating Claims Against Morphic Holding, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 15, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of morphic holding, inc. ("morphic" or "the company") (nasdaq:morf) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-11 03:30:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Morphic Holding, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 11, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of morphic holding, inc. ("morphic" or "the company") (nasdaq:morf) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-05 07:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Morphic Holding, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 5, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of morphic holding, inc. ("morphic" or "the company") (nasdaq:morf) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-04 03:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Morphic Holding, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 4, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of morphic holding, inc. ("morphic" or "the company") (nasdaq:morf) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Latest News
2024-03-05 16:05:00 - GlobeNewsWire
Morphic to Participate in March Investor Conferences
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.
2024-02-26 10:56:13 - Zacks Investment Research
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-14 11:00:20 - Zacks Investment Research
Best Momentum Stocks to Buy for February 14th
LUMN, SFST and MORF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2023.
2024-02-14 06:50:12 - Zacks Investment Research
New Strong Buy Stocks for February 14th
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
2024-02-08 10:55:17 - Zacks Investment Research
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
The consensus price target hints at a 57.2% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-05 11:18:10 - Zacks Investment Research
Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to an 110.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-03 16:05:00 - GlobeNewsWire
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D.
2023-12-20 11:16:16 - Zacks Investment Research
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-12-01 11:18:30 - Zacks Investment Research
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-11-09 13:33:31 - Zacks Investment Research
Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.